| Project/Area Number |
22659270
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
KANEKO Hiroshi 名古屋大学, 大学院・医学系研究科, 寄附講座助教 (60566975)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KITOH Hiroshi 名古屋大学, 医学部附属病院, 講師 (40291174)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,350,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2010: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | SOX9遺伝子 / 薬効スクリーニング / 軟骨細胞 / 軟骨再生 / オフラベル治療薬 / プロモーター / ルシフェラーゼ / 細胞培養 / SOX9 |
|---|
| Research Abstract |
A transcription factor SOX9 is a key regulator of cartilage metabolism. Overexpression of SOX9 gene in osteoarthritis(OA) articular cartilage stimulates extracellular matrix synthesis and the expression of extracellular matrix components can be restored to levels similar to those in normal. These results suggest that a drug able to enhance SOX9 gene expression is expected to improve symptoms of OA. We screened for off-label effects of 1, 184 chemical compounds approved by FDA to identify a drug able to enhance SOX9 gene expression by activating the promoter region. Finally, two compounds showed beneficial effects.
|
